6533b7d4fe1ef96bd12632a0

RESEARCH PRODUCT

Chronic l-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats

Peter JennerCarla CannizzaroB.c. TelAdrian M. OwenBai-yun ZengB. DassSarah Rose

subject

Malemedicine.medical_specialtyLevodopaanimal structuresTyrosine 3-MonooxygenaseReceptors DrugDopamine Agents-DOPANigrostriatal pathwayStriatumBiologySubthalamic nucleusStriatumLevodopaLesionAdrenergic AgentsDopamineInternal medicinemedicineAnimalsRNA MessengerRats WistarOxidopamineReceptors CannabinoidMedial forebrain bundleHydroxydopamineTyrosine hydroxylaseGeneral NeuroscienceMedial Forebrain BundleParkinson DiseaseCorpus StriatumRatsmedicine.anatomical_structureEndocrinologynervous systemSettore BIO/14 - Farmacologiamedicine.symptomCannabinoid CB1 receptor mRNA6-Hydroxydopaminemedicine.drug

description

Abstract The effect of a unilateral 6-hydroxydopamine (6-OHDA) lesion of the left medial forebrain bundle and 3 weeks treatment with l -DOPA of normal and 6-OHDA lesioned rats on CB1r mRNA expression was investigated by in situ hybridization. A 6-OHDA lesion of nigrostriatal pathway alone, confirmed by the loss of nigral tyrosine hydroxylase mRNA, did not alter CB1r mRNA levels in the dopamine depleted striatum. Similarly, chronic l -DOPA treatment of normal rats had no effect on striatal CB1r mRNA expression. In contrast, chronic l -DOPA treatment of 6-OHDA-lesioned rats significantly increased CB1r mRNA expression in the denervated striatum. These results suggest that the CB1r activity may be altered by l -DOPA's action and this may be related to the treatment of Parkinson's disease.

yearjournalcountryeditionlanguage
2000-01-07Neuroscience Letters
https://doi.org/10.1016/s0304-3940(99)00762-4